Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Most people think of vaccines as being "preventive," and taken to "prevent or lessen the impact of certain infectious ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

Real Housewives of Beverly Hills alum Teddi Mellencamp shared a health update regarding her cancer treatment via the Two Ts ...

Research exploring novel therapies to fight against bladder cancer and a world-first asthma study are among 18 Western projects drawing more than $15 ...

Western researchers recently attracted $15M in CIHR project grants, created “to support the bold ideas and innovative work of Canada’s health researchers.” ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

(9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been enrolled in the pivotal/registration Phase III clinical trial (AK112-310/HARMONi-GI2) of ivonescimab, a ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and ...

We expect Incyte Corporation INCY to surpass expectations when it reports second-quarter 2025 earnings on July 29, before the opening bell. The Zacks Consensus Estimate for the to-be-reported ...

Intervention/Treatment: The study is testing several interventions, including durvalumab, a known immunotherapy drug, in combination with other novel agents like danvatirsen, oleclumab, MEDI5752, and ...

ImCheck Therapeutics receives EMA Orphan Drug Designation for ICT01 for treatment for acute myeloid leukemia: Marseille, France Thursday, July 24, 2025, 15:00 Hrs [IST] ImCheck Th ...